These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature. Taira F; Horimoto Y; Saito M Breast Cancer; 2015 Nov; 22(6):664-8. PubMed ID: 23420376 [TBL] [Abstract][Full Text] [Related]
5. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098 [TBL] [Abstract][Full Text] [Related]
6. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. Shome D; Trent J; Espandar L; Hatef E; Araujo DM; Song CD; Kim SK; Esmaeli B Ophthalmology; 2008 Mar; 115(3):483-7. PubMed ID: 18201764 [TBL] [Abstract][Full Text] [Related]
7. Trastuzumab use for metastatic breast cancer in pregnancy. Sekar R; Stone PR Obstet Gynecol; 2007 Aug; 110(2 Pt 2):507-10. PubMed ID: 17666645 [TBL] [Abstract][Full Text] [Related]
8. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients]. Zhou NN; Teng XY; Liu DG; Xu R; Guan ZZ Ai Zheng; 2008 Dec; 27(12):1307-9. PubMed ID: 19079999 [TBL] [Abstract][Full Text] [Related]
9. Radiation recall dermatitis induced by trastuzumab. Moon D; Koo JS; Suh CO; Yoon CY; Bae J; Lee S Breast Cancer; 2016 Jan; 23(1):159-163. PubMed ID: 23543400 [TBL] [Abstract][Full Text] [Related]
10. [A long survival of a patient with poor performance status who suffered from advanced right breast cancer with multiple lung metastases controlled by trastuzumab as a key drug]. Fujikawa T; Mukai K; Tanaka A; Abe T; Yoshimoto Y; Tada S; Maekawa H; Shimoike N; Tanaka H; Kawashima T; Yokota T Gan To Kagaku Ryoho; 2012 Jun; 39(6):1009-12. PubMed ID: 22705704 [TBL] [Abstract][Full Text] [Related]
11. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report]. Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023 [TBL] [Abstract][Full Text] [Related]
12. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure. Walji N; Bhatt L; Dhallu S; Fernando IN Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923 [TBL] [Abstract][Full Text] [Related]
13. Bilateral Ulcerative Keratitis Associated With Afatinib Treatment for Non-Small-cell Lung Carcinoma. McKelvie J; McLintock C; Elalfy M Cornea; 2019 Mar; 38(3):384-385. PubMed ID: 30418275 [TBL] [Abstract][Full Text] [Related]
14. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients? Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z J BUON; 2012; 17(2):249-53. PubMed ID: 22740201 [TBL] [Abstract][Full Text] [Related]
15. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock]. Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270 [TBL] [Abstract][Full Text] [Related]
16. Psoriasis induced by trastuzumab therapy. de Lorenzi C; Kaya G; Quenan S Eur J Dermatol; 2018 Oct; 28(5):702-704. PubMed ID: 30378545 [No Abstract] [Full Text] [Related]
17. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N J BUON; 2013; 18(3):585-93. PubMed ID: 24065468 [TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793 [TBL] [Abstract][Full Text] [Related]
19. Peripheral ulcerative keratitis-like findings associated with filgrastim. Fraunfelder FW; Harrison D Cornea; 2007 Apr; 26(3):368-9. PubMed ID: 17413968 [TBL] [Abstract][Full Text] [Related]
20. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment]. Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]